NCT03792269

Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for mCRC

An Open-label, Randomized, Phase II Clinical Trial Comparing the Efficacy and Safety of Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for Metastatic Colorectal Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

XELOX as first-line treatment regimen has limited efficacy against patients with metastatic colorectal cancer (mCRC). Peritoneal metastasis is one of the most lethal factor for mCRC. Intraperitoneal chemotherapy has became a widely accepted strategy in the treatment of peritoneal dissemination. We hypothesized that combined multi-channel administration, such as intraperitoneal chemotherapy, oral chemotherapy, and intravenous chemotherapy, can produce better results than XELOX for first-line treatment for mCRC patients.

Conditions

• Colorectal Cancer Metastatic
• Chemotherapy Effect
• Chemotherapeutic Toxicity

Interventions

Type	Name	Description
DRUG	Irinotecan	intraperitoneal
DRUG	Oxaliplatin	intravenous
DRUG	Capecitabine

Timeline

• Start date: 2016-01-01
• Primary completion: 2019-12-01
• Completion: 2020-12-01
• First posted: 2019-01-03
• Last updated: 2019-01-03

Locations

1 site across 1 country: China